Prosecution Insights
Prosecution Insights
Listed by the USPTO as SZNAIDMAN, MARCOS L
Tech Center 1600 • Art Units: 1611 1612 1623 1628 1629
This examiner grants 37% of resolved cases
Marcos L. Sznaidman is a very high-volume examiner in Tech Center 1600 and Art Unit 1611, with 1272 resolved cases. He has an allowance rate of 37.3%, which suggests a rigorous examination process. The interview lift is 16.2%, indicating that interviews provide a helpful boost to the chances of success.
The median days to allowance is 1304. This timeline reflects a relatively long prosecution cycle in Art Unit 1611. With 1272 resolved cases, the 37.3% allowance rate and 16.2% interview lift are very robust metrics. Practitioners should be prepared for a challenging process but can use the 1304-day median to plan their strategy in Tech Center 1600. The 16.2% lift is a key tool for overcoming the 37.3% baseline allowance rate and moving cases toward a grant.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18389888 | METHODS OF TREATING GASTROINTESTINAL STROMAL TUMORS | Non-Final OA | Deciphera Pharmaceuticals, LLC |
| 18872672 | COMPOSITIONS COMPRISING DISODIUM 5,10-METHYLENE-(6R)-TETRAHYDROFOLATE | Non-Final OA | MERCK PATENT GMBH |
| 18373418 | COMPOSITIONS AND METHODS FOR IMPROVING CARDIAC STRUCTURE AND/OR FUNCTION | Non-Final OA | Wisconsin Alumni Research Foundation |
| 18353069 | Combination Therapeutics Comprising Nrf2 Agonists and Antivirals for Treating Viral Infections | Non-Final OA | The Regents of the University of California |
| 18007433 | METHODS FOR REDUCING GLYCOSPHINGOLIPID CONCENTRATION IN BRAIN TISSUE AND METHODS OF TREATMENT OF NEURODEGENERATIVE DISEASES INVOLVING THE SAME | Final Rejection | GENZYME CORPORATION |
| 18691617 | HETEROARYL-LINKED ANALOGS AS MGLU5 NEGATIVE ALLOSTERIC MODULATORS AND METHODS OF MAKING AND USING THE SAME | Non-Final OA | Vanderbilt University |
| 18691641 | PHENYL CORE COMPOUNDS AS MGLU5 NEGATIVE ALLOSTERIC MODULATORS AND METHODS OF MAKING AND USING THE SAME | Non-Final OA | Vanderbilt University |
| 18452885 | Use of Histamine Antagonists and Glucocorticoid for Treating and Preventing Neurodegenerative Diseases | Final Rejection | City University of Hong Kong |
| 18006541 | TARGETING IMMUNE PATHOLOGIES INDUCED BY HIGHLY PATHOGENIC CORONAVIRUSES | Final Rejection | National University of Singapore |
| 18604733 | N,N'-DIPHENYL-4,4'-BIPHENYLDICARBOXAMIDE ANALOGS AND THEIR USE IN CANCER TREATMENT | Non-Final OA | Board of Regents, The University of Texas System |
| 18028618 | USE OF SPHINGOSINE-1-PHOSPHATE RECEPTOR AGONIST | Final Rejection | LG CHEM, LTD. |
| 18363429 | NERVE AGENT DECONTAMINATING AGENTS | Non-Final OA | THE CURATORS OF THE UNIVERSITY OF MISSOURI |
| 18415139 | METHODS FOR TREATING PAIN | Final Rejection | Xenon Pharmaceuticals Inc. |
| 18277257 | LYSOSOME-ASSOCIATED MEMBRANE PROTEIN TARGETING COMPOUNDS AND USES THEREOF | Non-Final OA | RAMOT AT TEL-AVIV UNIVERSITY LTD. |
| 17912802 | USE OF A COMPOUND OR COMPOSITION COMPRISING AN INHIBITOR OF NLRP1 INFLAMMASOME ACTIVATION FOR THE TREATMENT OF HUMAN AIRWAY INFLAMMATION | Final Rejection | Agency for Science, Technology and Research |
| 18251670 | CXCR1/CXCR2 INHIBITORS FOR USE IN TREATING MYELOFIBROSIS | Non-Final OA | Icahn School of Medicine at Mount Sinai |
| 18566249 | PYRIDAZINES OR 1,2,4-TRIAZINES SUBSTITUTED BY SPIROCYCLIC AMINES | Non-Final OA | Janssen Pharmaceutica NV |
| 18572382 | HETEROCYCLIC EGFR INHIBITORS FOR USE IN THE TREATMENT OF CANCER | Non-Final OA | Blueprint Medicines Corporation |
| 18691426 | TREATMENT OF SLEEP DISTRUBANCES IN AUTISM SPECTRUM DISORDER PATIENTS | Non-Final OA | Vanda Pharmaceuticals Inc. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy37.4% of resolved applications examined by Marcos L Sznaidman were allowed (1,276 resolved cases), compared with 35.0% across Art Unit 1611 over the last five years.
This examiner's interview lift is +16.1 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.
Applications allowed by Marcos L Sznaidman took 1,304 days on average from filing to allowance.
Marcos L Sznaidman examines applications in Art Unit 1611 in Tech Center 1600 (Biotechnology & Pharmaceuticals).